Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 15-Feb-24 7:56 PM View:  | Wahlstrom Mats Director | Coherus Biosciences, Inc. (CHRS) | 09-Feb-24 | Gift | 99,988 | -- | -- | (50%) 199.98K to 99.99K | |
| 15-Feb-24 7:56 PM View: | Wahlstrom Mats Director | Coherus Biosciences, Inc. (CHRS) | 09-Feb-24 | Gift | 99,988 | -- | -- | 100% 99.99K to 199.98K | |
| 05-Feb-24 7:03 PM View: | Wahlstrom Mats Director | Coherus Biosciences, Inc. (CHRS) | 01-Feb-24 | Option Exercise | 59,988 | $1.67 | $100,000.00 | 150% 40.0K to 99.99K | |
| 23-Jan-24 8:05 PM View: | Reider Paul Chief Commercial Officer | Coherus Biosciences, Inc. (CHRS) | 20-Jan-24 | Payment of Exercise | 4,854 | $2.44 | $11,843.80 | (6%) 86.13K to 81.28K | |
| 23-Jan-24 8:07 PM View: | Lanfear Dennis M President & CEO Director | Coherus Biosciences, Inc. (CHRS) | 20-Jan-24 | Payment of Exercise | 11,218 | $2.44 | $27,371.90 | (< 1%) 1.24M to 1.23M | |
| 23-Jan-24 8:04 PM View: | McMichael Bryan J See Remarks | Coherus Biosciences, Inc. (CHRS) | 20-Jan-24 | Payment of Exercise | 1,707 | $2.44 | $4,165.08 | (7%) 24.68K to 22.97K | |
| 09-Jan-24 7:37 PM View: | McMichael Bryan J See Remarks | Coherus Biosciences, Inc. (CHRS) | 07-Jan-24 | Payment of Exercise | 1,707 | $2.87 | $4,899.09 | (6%) 26.39K to 24.68K | |
| 08-Jan-24 7:04 PM View: | Lanfear Dennis M President & CEO Director | Coherus Biosciences, Inc. (CHRS) | 04-Jan-24 | Payment of Exercise | 11,781 | $2.92 | $34,400.50 | (< 1%) 1.25M to 1.24M | |
| 08-Jan-24 6:58 PM View: | Reider Paul Chief Commercial Officer | Coherus Biosciences, Inc. (CHRS) | 04-Jan-24 | Payment of Exercise | 2,275 | $2.92 | $6,643.00 | (3%) 88.41K to 86.13K | |
| 03-Jan-24 4:42 PM View: | Stilwell McDavid Chief Financial Officer | Coherus Biosciences, Inc. (CHRS) | 31-Dec-23 | Payment of Exercise | 18,440 | $3.33 | $61,405.20 | (20%) 93.75K to 75.31K | |
| 15-Dec-23 4:47 PM View: | Reider Paul Chief Commercial Officer | Coherus Biosciences, Inc. (CHRS) | 13-Dec-23 | Payment of Exercise | 2,049 | $2.37 | $4,856.13 | (2%) 90.45K to 88.41K | |
| 24-Nov-23 4:04 PM View: | Lanfear Dennis M President & CEO Director | Coherus Biosciences, Inc. (CHRS) | 22-Nov-23 | Option Sale | 223,100 | $2.02 | $449,770.00 | (15%) 1.47M to 1.25M | |
| 24-Nov-23 4:04 PM View: | Lanfear Dennis M President & CEO Director | Coherus Biosciences, Inc. (CHRS) | 22-Nov-23 | Option Exercise | 299,940 | $1.42 | $425,015.00 | 26% 1.17M to 1.47M | |
| 04-Apr-23 8:56 PM View: | Stilwell McDavid Chief Financial Officer | Coherus Biosciences, Inc. (CHRS) | 01-Apr-23 | Payment of Exercise | 3,457 | $6.84 | $23,645.90 | (3%) 105.71K to 102.25K | |
| 04-Apr-23 8:57 PM View: | Reider Paul Chief Commercial Officer | Coherus Biosciences, Inc. (CHRS) | 01-Apr-23 | Payment of Exercise | 2,451 | $6.84 | $16,764.80 | (3%) 89.5K to 87.05K | |
| 04-Apr-23 9:02 PM View: | Vexler Vladimir Chief Scientific Officer | Coherus Biosciences, Inc. (CHRS) | 31-Mar-23 | Payment of Exercise | 16,278 | $6.84 | $111,342.00 | (12%) 132.64K to 116.36K | |
| 24-Jan-23 4:50 PM View: | Lanfear Dennis M President & CEO Director | Coherus Biosciences, Inc. (CHRS) | 20-Jan-23 | Grant | 86,250 | -- | -- | 8% 1.09M to 1.17M | |
| 24-Jan-23 4:45 PM View: | Stilwell McDavid Chief Financial Officer | Coherus Biosciences, Inc. (CHRS) | 20-Jan-23 | Grant | 40,000 | -- | -- | 62% 64.24K to 104.24K | |
| 24-Jan-23 4:49 PM View: | McMichael Bryan J See Remarks | Coherus Biosciences, Inc. (CHRS) | 20-Jan-23 | Grant | 12,500 | -- | -- | 90% 13.89K to 26.39K | |
| 24-Jan-23 4:47 PM View: | Vexler Vladimir Chief Scientific Officer | Coherus Biosciences, Inc. (CHRS) | 20-Jan-23 | Grant | 40,000 | -- | -- | 44% 91.32K to 131.32K | |
| 12-Jan-23 4:37 PM View: | Vexler Vladimir Chief Scientific Officer | Coherus Biosciences, Inc. (CHRS) | 11-Jan-23 | Payment of Exercise | 3,602 | $10.26 | $36,956.50 | (4%) 94.92K to 91.32K | |
| 12-Jan-23 4:37 PM View: | Vexler Vladimir Chief Scientific Officer | Coherus Biosciences, Inc. (CHRS) | 10-Jan-23 | Payment of Exercise | 3,602 | $9.85 | $35,479.70 | (4%) 98.53K to 94.92K | |
| 10-Jan-23 4:40 PM View: | McMichael Bryan J See Remarks | Coherus Biosciences, Inc. (CHRS) | 07-Jan-23 | Payment of Exercise | 1,699 | $9.58 | $16,276.40 | (11%) 15.59K to 13.89K | |
| 06-Jan-23 6:15 PM View: | Vexler Vladimir Chief Scientific Officer | Coherus Biosciences, Inc. (CHRS) | 04-Jan-23 | Payment of Exercise | 5,437 | $9.87 | $53,663.20 | (5%) 103.96K to 98.53K | |
| 06-Jan-23 6:17 PM View: | Lanfear Dennis M President & CEO Director | Coherus Biosciences, Inc. (CHRS) | 04-Jan-23 | Payment of Exercise | 10,905 | $9.87 | $107,632.00 | (< 1%) 1.1M to 1.09M | |
| 06-Jan-23 6:14 PM View: | Stilwell McDavid Chief Financial Officer | Coherus Biosciences, Inc. (CHRS) | 04-Jan-23 | Payment of Exercise | 5,437 | $9.87 | $53,663.20 | (8%) 69.68K to 64.24K | |
| 04-Jan-23 6:44 PM View: | Lanfear Dennis M President & CEO Director | Coherus Biosciences, Inc. (CHRS) | 30-Dec-22 | Gift | 4,000 | -- | -- | (< 1%) 1.1M to 1.1M | |
| 05-Apr-22 5:19 PM View: | Stilwell McDavid Chief Financial Officer | Coherus Biosciences, Inc. (CHRS) | 01-Apr-22 | Payment of Exercise | 3,458 | $12.85 | $44,435.30 | (5%) 73.14K to 69.68K | (11%) |
| 05-Apr-22 5:19 PM View: | Vexler Vladimir Chief Scientific Officer | Coherus Biosciences, Inc. (CHRS) | 01-Apr-22 | Payment of Exercise | 3,458 | $12.85 | $44,435.30 | (3%) 107.42K to 103.96K | (11%) |
| 01-Mar-22 8:22 PM View: | Wahlstrom Mats Director | Coherus Biosciences, Inc. (CHRS) | 28-Feb-22 | Grant | 29,994 | $2.08 | $62,501.50 | 300% 10.01K to 40.0K | |
| 01-Mar-22 8:22 PM View: | Wahlstrom Mats Director | Coherus Biosciences, Inc. (CHRS) | 25-Feb-22 | Grant | 10,006 | $11.64 | $116,433.00 | 100% 0 to 10.01K | |
| 12-Jan-22 4:39 PM View: | Vexler Vladimir Chief Scientific Officer | Coherus Biosciences, Inc. (CHRS) | 11-Jan-22 | Payment of Exercise | 3,583 | $14.36 | $51,451.90 | (3%) 111.0K to 107.42K | < 1% |
| 12-Jan-22 4:39 PM View: | Vexler Vladimir Chief Scientific Officer | Coherus Biosciences, Inc. (CHRS) | 10-Jan-22 | Payment of Exercise | 4,150 | $14.30 | $59,345.00 | (4%) 115.15K to 111.0K | < 1% |
| 06-Jan-22 7:50 PM View: | Lanfear Dennis M President & CEO Director | Coherus Biosciences, Inc. (CHRS) | 04-Jan-22 | Grant | 86,250 | -- | -- | 8% 1.02M to 1.1M | |
| 06-Jan-22 7:48 PM View: | Vexler Vladimir Chief Scientific Officer | Coherus Biosciences, Inc. (CHRS) | 04-Jan-22 | Grant | 40,000 | -- | -- | 53% 75.15K to 115.15K | |
| 06-Jan-22 7:50 PM View: | Stilwell McDavid Chief Financial Officer | Coherus Biosciences, Inc. (CHRS) | 04-Jan-22 | Grant | 40,000 | -- | -- | 121% 33.14K to 73.14K | |
| 23-Nov-21 5:00 PM View: | Lanfear Dennis M President & CEO Director | Coherus Biosciences, Inc. (CHRS) | 17-Nov-21 | Gift | 10,000 | -- | -- | (< 1%) 1.03M to 1.02M | |
| 19-Oct-21 7:36 PM View: | Stilwell McDavid Chief Financial Officer | Coherus Biosciences, Inc. (CHRS) | 15-Oct-21 | Market Sale | 3,507 | $16.80 | $58,918.70 | (10%) 35.12K to 31.61K | (2%) |
| 29-Sep-21 8:18 PM View: | Healy James Director | Coherus Biosciences, Inc. (CHRS) | 29-Sep-21 | Market Sale | 286,076 | $16.12 | $4,611,550.00 | (80%) 356.16K to 70.09K | (5%) |
| 29-Sep-21 8:18 PM View: | Healy James Director | Coherus Biosciences, Inc. (CHRS) | 28-Sep-21 | Market Sale | 48,329 | $17.17 | $829,809.00 | (12%) 404.49K to 356.16K | 2% |
| 29-Sep-21 8:18 PM View: | Healy James Director | Coherus Biosciences, Inc. (CHRS) | 27-Sep-21 | Market Sale | 100,150 | $18.06 | $1,808,710.00 | (20%) 504.64K to 404.49K | 6% |
| 08-Jul-21 5:19 PM View: | Anicetti Vincent R Chief Operating Officer | Coherus Biosciences, Inc. (CHRS) | 06-Jul-21 | Grant | 50,000 | -- | -- | 67% 74.79K to 124.79K | |
| 10-Jun-21 4:35 PM View: | Stilwell McDavid Chief Financial Officer | Coherus Biosciences, Inc. (CHRS) | 09-Jun-21 | Market Purchase | 3,700 | $13.42 | $49,667.70 | 12% 31.42K to 35.12K | < 1% |
| 08-Jun-21 5:11 PM View: | Lanfear Dennis M President & CEO Director | Coherus Biosciences, Inc. (CHRS) | 08-Jun-21 | Option Exercise | 31,054 | $0.42 | $12,943.30 | 3% 1.03M to 1.06M | |
| 08-Jun-21 5:11 PM View: | Lanfear Dennis M President & CEO Director | Coherus Biosciences, Inc. (CHRS) | 08-Jun-21 | Market Option Sale | 31,054 | $13.56 | $421,229.00 | (3%) 1.06M to 1.03M | |
| 08-Jun-21 5:11 PM View: | Lanfear Dennis M President & CEO Director | Coherus Biosciences, Inc. (CHRS) | 06-Jun-21 | Option Exercise | 300,000 | $0.42 | $125,040.00 | 41% 726.91K to 1.03M | |
| 30-Apr-21 4:39 PM View: | Anicetti Vincent R Chief Operating Officer | Coherus Biosciences, Inc. (CHRS) | 28-Apr-21 | Grant | 20,000 | -- | -- | 37% 53.4K to 73.4K | |
| 30-Apr-21 4:37 PM View: | Vexler Vladimir Chief Scientific Officer | Coherus Biosciences, Inc. (CHRS) | 28-Apr-21 | Grant | 20,000 | -- | -- | 37% 53.39K to 73.39K | |
| 30-Apr-21 4:38 PM View: | Stilwell McDavid Chief Financial Officer | Coherus Biosciences, Inc. (CHRS) | 28-Apr-21 | Grant | 20,000 | -- | -- | 200% 10.0K to 30.0K | |
| 11-Mar-21 5:37 PM View: | Vexler Vladimir Chief Scientific Officer | Coherus Biosciences, Inc. (CHRS) | 09-Mar-21 | Market Option Sale | 102,480 | $16.25 | $1,665,180.00 | (61%) 167.63K to 65.15K |
